186 results on '"Tuntland, Tove"'
Search Results
2. Supplementary Table 4 from Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma
3. Supplementary Figure 4 from Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma
4. Supplementary Table 1 from Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma
5. Supplementary Table 3 from Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma
6. Supplementary Figure 3 from Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma
7. Supplementary Figure Legend from Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma
8. Use of solubilizers in preclinical formulations: Effect of Cremophor EL on the pharmacokinetic properties on early discovery compounds
9. Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness
10. A modern in vivo pharmacokinetic paradigm: combining snapshot, rapid and full PK approaches to optimize and expedite early drug discovery
11. TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts
12. Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery
13. A small molecule accelerates neuronal differentiation in the adult rat
14. Snapshot PK: a rapid rodent in vivo preclinical screening approach
15. Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors
16. Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases
17. Efflux of Zidovudine and 2′,3′-Dideoxyinosine Out of the Cerebrospinal Fluid When Administered Alone and in Combination to Macaca nemestrina
18. In vitro models to predict the in vivo mechanism, rate, and extent of placental transfer of dideoxynucleoside drugs against human immunodeficiency virus
19. Integrating pharmacokinetic-pharmacodynamic modeling in preclinical assessment of mutant selective EGFR covalent tyrosine kinase inhibitor EGF816
20. Mechanism and rate of placental transfer of zalcitabine (2',3'-dideoxycytidine) in Macaca nemestrina
21. Design and synthesis of novel selective anaplastic lymphoma kinase inhibitors
22. Identification of Potent and Selective RIPK2 Inhibitors for the Treatment of Inflammatory Diseases
23. Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma
24. Novel tricyclic pyrazolopyrimidines as potent and selective GPR119 agonists
25. Discovery of structurally novel, potent and orally efficacious GPR119 agonists
26. A Type-II Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of Bcr-Abl
27. Design, synthesis, and structure–activity-relationship of phenyl imidazoles as potent Smoothened antagonists
28. Antitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease
29. (R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors
30. Targeting wild-type and T315I Bcr-Abl by combining allosteric with ATP-site inhibitors
31. Discovery of novel 1H-imidazol-2-yl-pyrimidine-4,6-diamines as potential antimalarials
32. TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts
33. Abstract B42: Combinatorial CDK4/6 and ALK inhibition demonstrates on-target synergy against neuroblastoma
34. Abstract 1000: Combination CDK4/6 and ALK inhibition demonstrates on-target synergy against neuroblastoma
35. Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research
36. Lead Optimization of Imidazopyrazines: A New Class of Antimalarial with Activity on Plasmodium Liver Stages
37. Cell-based optimization of novel benzamides as potential antimalarial leads
38. Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials
39. Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator
40. Discovery and biological evaluation of benzo[ a]carbazole-based small molecule agonists of the thrombopoietin (Tpo) receptor
41. Imidazolopiperazines: Lead Optimization of the Second-Generation Antimalarial Agents
42. Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models
43. A Chemically Induced Vaccine Strategy for Prostate Cancer
44. Imidazolopiperazines: Hit to Lead Optimization of New Antimalarial Agents
45. Transient expression of an IL-23R extracellular domain Fc fusion protein in CHO vs. HEK cells results in improved plasma exposure
46. Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist
47. Novel Bisaryl Substituted Thiazoles and Oxazoles as Highly Potent and Selective Peroxisome Proliferator-Activated Receptor δ Agonists
48. Modulation of TNFα, IL-10 and IL-12p40 levels by a ceramide-1-phosphate analog, PCERA-1, in vivo and ex vivo in primary macrophages
49. Synthesis and SAR of succinamide peptidomimetic inhibitors of cathepsin S
50. Discovery and biological evaluation of benzo[a]carbazole-based small molecule agonists of the thrombopoietin (Tpo) receptor
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.